Molecular aspects of multiple myeloma

Journal of Clinical Pathology - Molecular Pathology

Volumn 55, Issue 5, 2002, Pages 273-283

  Pratt, G ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN HEAVY CHAIN;

BONE MARROW; CANCER SURVIVAL; CHROMOSOME 14Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DISEASE COURSE; GENE EXPRESSION; GENETIC DISORDER; HUMAN; KARYOTYPE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TUMOR CELL;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 14; CYTOKINES; DISEASE PROGRESSION; HUMANS; KARYOTYPING; MULTIPLE MYELOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 0036796603     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.55.5.273     Document Type: Review

References (121)

1. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996;94:217-27.
2. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridisation identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995;86:3915-21.
3. Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within plasma cells. Br J Haematol 1995;90:693-6.
4. Fonseca R, Aguayo P, Ahmann GJ, et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve serial partner chromosomes [abstract]. Blood 1999;10(suppl 1):2943.
5. Hallek M, Bersagel PL, Anderson K. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
6. DeWald G, Kyle R, Hicks G, et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukaemia or amyloidosis. Blood 1985;66:380-90.
7. Gould J, Alexanian R, Goodacre A, et al. Plasma cell karyotype in multiple myeloma. Blood 1988;7:453-6.
8. Weh H, Gutensohn K, Selbach J, et al. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 1993;29:1269-73.
9. Sawyer JR, Waldron JA, Jagannath S, et al. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-9.
10. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-6.
11. Lai JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995;85:2490-7.
12. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997;18:84-93.
13. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998;101:189-94.
14. Facon T, Lai JL, Preudhomme C, et al. Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients. Br J Haematol 1993;84:743-5.
15. Smadja NV, Louvet C, Isnard F, et al. Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. Br J Haematol 1995;90:619-24.
16. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998;12:960-9.
17. Latreille J, Barlogie B, Gohde W, et al. Cellular DNA content as a marker of human multiple myeloma. Blood 1980;55:403-8.
18. Barlogie B, Alexanian R, Dixon D, et al. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985;66:338-41.
19. Lee W, Han K, Drut RM, et al. Use of fluorescence in situ hybridisation for retrospective detection of aneuploidy in multiple myeloma. Genes Chromosomes Cancer 1993;7:137-43.
20. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridisation. Cancer Res 1995;55:3854-9.
21. Flactif M, Zandecki M, Lai JL, et al. Interphase fluorescence in situ hybridisation as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 1995;9:2109-14.
22. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997;15:2659-66.
23. Avet-Loiseau H, Andree-Ashley LE, Moore D, et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukaemia measured using comparative genomic hybridisation. Genes Chromosomes Cancer 1997;19:124-33.
24. Cigudosa JC, Rao PH, Calasanz MJ, et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridisation. Blood 1998;91:3007-10.
25. Rao PH, Cigudosa JC, Ning Y, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 1998;92:1743-8.
26. Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998;92:4269-78.
27. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-22.
28. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel protooncogenes. Annu Rev Immunol 1992;10:785-807.
29. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001;20:5580-94.
30. Bersagel PL, Chesi M, Nardini E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 1996;93:13931-6.
31. Nishida K, Tamura A, Nakazawa N, et al. The IgG heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukaemia as detected by in situ hybridisation. Blood 1997;90:526-34.
32. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58:5640-5.
33. Avet-Loiseau H, Brigaudeau C, Morineau N, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridisation. Genes Chromosomes Cancer 1999;24:9-15.
34. Martelli ML, Gabrea A, Qi Y, et al. Immunoglobulin translocations in multiple myeloma: present in all cell lines but not all primary tumours. Blood 1999;10(suppl 1):2431.
35. Ho PJ, Brown RD, Pelka GJ, et al. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. Blood 2001;97:490-5.
36. Withdrawn.
37. Gabrea A, Bergsagel PL, Chesi M, et al. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumour cell. Molecular Cell 1999;3:119-23.
38. Pratt G, Fenton JAL, Davies FE, et al. Insertional events as well as translocations may arise during aberrant immunoglobulin switch recombination in a patient with multiple myeloma. Br J Haematol 2001;112:388-91.
39. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed but correlate with natural history, immunological features and clinical presentation. Blood 2002;99:2185-91.
40. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002;99:3735-41.
41. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possibly early events in patients with primary systemic amyloidosis. Blood 2001;98:2266-8.
42. Fonseca R, Witzig TE, Gertz MA, et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol 1998;101:296-301.
43. Williams ME, Swerdlow SH, Rosenberg CL, et al. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. Leukemia 1993;7:241-5.
44. Janssen JWG, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with a t(11;14)(q13;q32). Blood 2000;95:2691-8.
45. Ronchetti D, Finelli P, Richelda R, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 1999;93:1330-7.
46. Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 1992;7:1401-6.
47. Raynaud SD, Bekri S, Leroux D, et al. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosomes Cancer 1993;8:80-7.
48. Meeus P, Stul MS, Mecucci C, et al. Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. Cancer Genet Cytogenet 1995;83:25-7.
49. Chesi M, Bergsagel PL, Brents LA, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996;88:674-81.
50. Komatsu H, Iida S, Yamamoto K, et al. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood 1994;84:1226-31.
51. Lai JL, Michaux L, Dastugue N, et al. Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant. Cancer Genet Cytogenet 1998;104:133-8.
52. Finelli P, Fabris S, Zagano S, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in-situ hybridisation. Blood 1999;94:724-32.
53. Malgeri U, Baldini L, Perfetti V, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 2000;60:4058-61.
54. Chesi M, Nardini E, Lim RSC, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-34.
55. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-4.
56. Stec I, Wright TJ, van Ommen GJB, et al. WHSC-1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998;7:1071-82.
57. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000;95:992-8.
58. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97:729-36.
59. Li Z, Zhu YX, Plowright EE, et al. The myeloma associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001;97:2413-19.
60. Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol 2001;114:362-4.
61. Ronchetti D, Greco A, Compasso S, et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001;20:3553-62.
62. Still IH, Vince P, Cowell JK. The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to the translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 1999;58:165-70.
63. Fonseca R, Oken MM, Greipp PR. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of uncertain significance. Blood 2001;98:1271-2.
64. Nishizawa M, Kataoka K, Goto N, et al. V-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc Natl Acad Sci U S A 1989;86:7711-15.
65. Kataoka K, Nishizawa M, Kawai S. Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. J Virol 1993;67:2133-41.
66. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-73.
67. Shaughnessy J, Gabrea A, Ying Q, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001;98:217-23.
68. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997;17:226-30.
69. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001;14:277-89.
70. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolor spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001;112:167-74.
71. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97:228-33.
72. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple tumors. Blood 2001;98:3082-6.
73. Iida S, Rao PH, Nallasivam P, et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996;88:4110-17.
74. Avet-Loiseau H, Li JY, Morineau N, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 1999;94:2583-9.
75. Zojer N, Konigsberg R, Ackermann J, et al. In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood 2000;95:1925-30.
76. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000;96:1505-11.
77. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.
78. Ng MHL, Chung YF, Lo KW, et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997;87:2500-6.
79. Urashima M, Teoh G, Ogata A, et al. Role of CDK4 and p16INK4A in interleukin-6 mediated growth of multiple myeloma. Leukemia 1997;11:1957-63.
80. INK4A genes in multiple myeloma. Br J Haematol 1997;96:98-102.
81. INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001;98:244-6.
82. Uchida T, Kinoshita T, Ohno T, et al. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 2001;15:157-65.
83. WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 1997;90:279-89.
84. Portier M, Moles JP, Mazars GR, et al. P53 and RAS gene mutations in multiple myeloma. Oncogene 1992;7:2539-43.
85. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 1993;81:2708-13.
86. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the eastern cooperative oncology group phase III trial. Blood 1996;88:2699-706.
87. Billadeau D, Jelinek DF, Shah N, et al. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 1995;55:3640-6.
88. Kalakonda N, Rothwell DG, Scarffe JH, et al. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001;98:1555-60.
89. Liu P, Rowley M, Van Ness B. Wildtype Rb and p53 can suppress autocrine IL-6 production and proliferation of U266 myeloma cells [abstract]. Blood 1996;88(suppl 1):100a.
90. Mazars GR, Portier M, Zhang XG, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1993;8:1107.
91. Neri A, Baldini L, Trecca D, et al. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993;81:128-35.
92. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional dose chemotherapy. Blood 1998;92:802-7.
93. Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood 1996;88:2219-27.
94. Zandecki M, Facon T, Preudhomme C, et al. The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. Leuk Lymphoma 1995;18:497.
95. Juge-Morineau N, Mellerin MP, et al. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 1995;91:664-7.
96. Vincent T, Jourdan M, Sy MS, et al. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6 mediated pathway involving the phosphorylation of retinoblastoma protein. J Biol Chem 2001;276:14728-36.
97. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1302.
98. Silvestris F, Tucci M, Cafforio P, et al. Fas-L upregulation by highly malignant myeloma plasma cells: role in the pathogenesis of anaemia and disease progression. Blood 2001;97:1155-64.
99. Pettersson M, Jernberg-Wiklund H, Larsson LG, et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992;79:495-502.
100. Ong F, Nieuwkoop JA, De Groot-Swings GMJS, et al. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995;9:1282-4.
101. L. Cancer Res 1995;55:2262-5.
102. Tian E, Gazitt Y. The role of p53, bcl-2 and bax network in dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 1996;8:719-26.
103. Miguel-Garcia A, Orero T, Matutes E, et al. Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica 1998;83:298-304.
104. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000;96:3560-8.
105. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood 2002;99:1745-57.
106. Klein B, Zhang XG, Lu ZY, et al. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
107. Davies FE, Anderson KC. Novel therapeutic targets in multiple myeloma. Eur J Haematol 2000;64:359-67.
108. Rawstron AC, Fenton JAL, Ashcroft J, et al. The IL-6 receptor alpha chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000;96:3880-6.
109. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355:248-9.
110. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of multiple myeloma. Blood 1999;9:3064-73.
111. Seidel C, Borset M, Hjertner O, et al. High levels of soluble syndecan-1 in myeloma derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000;96:3139-46.
112. Podar K, Yu-Tzu T, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
113. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33.
114. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40.
115. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
116. Rettig MB, Ma HJ, Vescio RA, et al. Kaposi's sarcoma-associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997;276:1851-4.
117. Tarte K, Chang Y, Klein B. Kaposi's sarcoma-associated herpes virus and multiple myeloma: lack of criteria for causality. Blood 1999;10:3159-63.
118. Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-38.
119. Pourgourides E, Heath C, Melo JV, et al. Specific action of FGFR inhibitors against t(4;14) positive myeloma cells [abstract]. Blood 2001;98(suppl 1):1560.
120. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human myeloma cells. Cancer Res 2001;61:3071-6.
121. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.